Mangalam Drugs and Organics Ltd (MANGALAM) — shareholding pattern, promoter holding, financials and share price
About Mangalam Drugs and Organics Ltd (MANGALAM)
Mangalam Drugs and Organics Ltd operates in the Pharmaceuticals industry, within the Healthcare sector. It trades on the NSE as MANGALAM and on the BSE under scrip code 532637. Its ISIN is INE584F01014.
Incorporated in 1977, Mangalam Drugs & Organics Ltd manufactures Active Pharmaceutical Ingredients and Intermediates. [1]
Mangalam Drugs and Organics Ltd is a chemical manufacturing company specializing in active pharmaceutical ingredients, perfumery, dye intermediates, and bulk drug intermediates. Established in 1972, its key facilities are located in Vapi and Sangamner.
The company has a strong manufacturing setup with significant production capacity expansions over the years, signaling its strategic focus on growth and scale in bulk drugs.
Listed peers in Pharmaceuticals: Vivimed Labs Ltd, Shelter Pharma Ltd, Vista Pharmaceuticals Ltd, ANG Lifesciences India Ltd, Rajnish Wellness Ltd, Sandu Pharmaceuticals Ltd.
Valuation & Returns
10 Jul 2026At ₹28 a share on 10 Jul 2026, Mangalam Drugs and Organics Ltd (MANGALAM) was valued at a price-to-earnings ratio of -1x against an industry P/E of 36.41x and a price-to-book of 0.3x on a book value of ₹94.12 per share as of Mar 2025. Solomo computes return on equity of -29.81% and return on capital employed of -13.6% from filed results. Earnings ratios use consolidated results for the twelve months Jun 2025 to Mar 2026.
- P/E
- -1x
- Industry P/E
- 36.41x
- P/B
- 0.3x
- EPS (TTM)
- ₹-28.06
- Book value / share
- ₹94.12
- ROE
- -29.81%
- ROCE
- -13.6%
- ROA
- -12.12%
- Debt / equity
- 0.6x
- Dividend yield
- 0%
- EBITDA margin
- -6.09%
- 52-week range
- ₹22.7 – ₹94.4
Ratios are computed from filed results and the last recorded price. Not investment advice.
Financial Performance
Mar 2026In the year ended Mar 2026, Mangalam Drugs and Organics Ltd (MANGALAM) reported revenue of ₹232 crore, net profit of ₹-44 crore and earnings per share of ₹-28.05. That compares with revenue of ₹318 crore and net profit of ₹7 crore in Mar 2025. Figures are consolidated, as filed with the exchanges.
In the quarter ended Mar 2026, revenue was ₹67 crore and net profit ₹-13 crore (consolidated).
| Metric | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|
| Revenue (₹ cr) | 369 | 318 | 232 |
| Net profit (₹ cr) | -9 | 7 | -44 |
| EPS (₹) | -5.73 | 4.25 | -28.05 |
| Measure | 10Y | 5Y | 3Y | 1Y |
|---|---|---|---|---|
| Sales growth | 0.54% | 0.32% | -10.98% | -13.66% |
| Profit growth | -8.91% | -3.45% | -29.38% | 174.09% |
| Stock price CAGR | -17% | -30% | -37% | -68% |
Ownership Summary
Jun 2026As of Jun 2026, promoters hold 35.65% of Mangalam Drugs and Organics Ltd (MANGALAM) (unchanged from the previous quarter), foreign institutional investors (FII) hold 0.11% and domestic institutional investors (DII) hold 0%. Market capitalisation was ₹44 crore on 10 Jul 2026. Shareholding is filed quarterly with BSE and NSE; Solomo carries every filing back to Jun 2005.
Largest disclosed public shareholders in Jun 2026: HUF 1.5%, Thakkalapalli Sampath Rao 1.03%, Anish Dwivedi 1.01%. Only stakes above the 1% disclosure threshold are named in filings.
| Quarter | Promoter | Pledged | FII | DII | Public |
|---|---|---|---|---|---|
| Jun 2026 | 35.65% | - | 0.11% | 0% | 64.35% |
| Mar 2026 | 35.65% | - | 0.32% | 0% | 64.35% |
| Dec 2025 | 35.64% | 7.1% | 0.13% | 0% | 64.36% |
| Sep 2025 | 50.3% | 34.6% | 0.11% | 0% | 49.7% |
| Jun 2025 | 50.3% | 13.2% | 0.53% | 0% | 49.7% |
| Mar 2025 | 50.3% | 13.2% | 0.47% | 0% | 49.7% |
| Dec 2024 | 50.3% | 11% | 0.11% | 0% | 49.7% |
| Sep 2024 | 50.3% | 10.3% | 0.11% | 0% | 49.7% |